ATE267394T1 - Nachweis der krankheitsbedingten konformation eines proteins - Google Patents

Nachweis der krankheitsbedingten konformation eines proteins

Info

Publication number
ATE267394T1
ATE267394T1 AT98906471T AT98906471T ATE267394T1 AT E267394 T1 ATE267394 T1 AT E267394T1 AT 98906471 T AT98906471 T AT 98906471T AT 98906471 T AT98906471 T AT 98906471T AT E267394 T1 ATE267394 T1 AT E267394T1
Authority
AT
Austria
Prior art keywords
prp
conformation
protein
concentration
binding partner
Prior art date
Application number
AT98906471T
Other languages
English (en)
Inventor
Stanley B Prusiner
Jiri G Safar
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE267394T1 publication Critical patent/ATE267394T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2872Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0337Animal models for infectious diseases
    • A01K2267/0343Animal model for prion disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20Immunohistochemistry assay
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/961Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
AT98906471T 1997-02-21 1998-02-20 Nachweis der krankheitsbedingten konformation eines proteins ATE267394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/804,536 US5891641A (en) 1997-02-21 1997-02-21 Assay for disease related conformation of a protein
PCT/US1998/002992 WO1998037411A1 (en) 1997-02-21 1998-02-20 Assay for disease related conformation of a protein

Publications (1)

Publication Number Publication Date
ATE267394T1 true ATE267394T1 (de) 2004-06-15

Family

ID=25189206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906471T ATE267394T1 (de) 1997-02-21 1998-02-20 Nachweis der krankheitsbedingten konformation eines proteins

Country Status (10)

Country Link
US (1) US5891641A (de)
EP (2) EP1416281A3 (de)
JP (1) JP3774236B2 (de)
AT (1) ATE267394T1 (de)
AU (1) AU725844B2 (de)
BR (1) BR9807600A (de)
CA (1) CA2278577A1 (de)
DE (2) DE69823985T2 (de)
ES (1) ES2218807T3 (de)
WO (1) WO1998037411A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
US6620629B1 (en) * 1997-02-21 2003-09-16 The Regents Of The University Of California Method for detecting prions
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
KR20010041135A (ko) * 1998-02-20 2001-05-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단백질의 다중의 질병 관련된 입체구조의 특이적인스트레인에 대한 분석
US6127130A (en) 1998-03-13 2000-10-03 The United States Of America As Represented By The Secretary Of The Navy Multiassay method for determining the concentrations of antigens and interferants
GB2371049B (en) * 1998-11-04 2003-06-04 Imp College Innovations Ltd Methods of making antibodies against ß-forms of prion proteins and their uses
GB2362385B (en) * 1998-11-04 2002-06-19 Imp College Innovations Ltd Non-aggregated ß-forms of prion proteins
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US6821738B2 (en) * 1999-01-20 2004-11-23 The Board Of Regents For Oklahoma State University Broad spectrum bio-detection of nerve agents, organophosphates, and other chemical warfare agents
US6605445B1 (en) * 1999-02-22 2003-08-12 Bayer Corporation Rapid method of determining clearance of prion protein
GB9904395D0 (en) * 1999-02-25 1999-04-21 Fluorescience Ltd Protein assay
US6972198B2 (en) * 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
GB9908059D0 (en) 1999-04-09 1999-06-02 Imp College Innovations Ltd Diagnosis and treatment of diseases
DE19918141A1 (de) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
NZ516240A (en) * 1999-06-23 2005-11-25 Caprion Pharmaceuticals Inc Prion protein peptides and uses thereof
US6537548B1 (en) * 2000-07-27 2003-03-25 The Regents Of The University Of California Antibodies specific for ungulate PrP
EP1399110A4 (de) * 2001-05-01 2004-12-01 Univ California Antikörper eliminieren die prionen-ausbreitung und unterstützen die beseitigung der infektivität
EP1395833B1 (de) 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US20030050517A1 (en) * 2001-07-31 2003-03-13 Ahting Herbert C. Process for producing glycerin
WO2003027631A2 (en) * 2001-09-20 2003-04-03 The Regents Of The University Of California Muscle sample prepared for prion assay
US7803315B2 (en) * 2001-10-05 2010-09-28 American Sterilizer Company Decontamination of surfaces contaminated with prion-infected material with gaseous oxidizing agents
DE10152677A1 (de) 2001-10-19 2003-05-08 Aventis Behring Gmbh Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren
US7045297B2 (en) * 2001-11-14 2006-05-16 Prion Developmental Laboratories, Inc. Rapid prion-detection assay
US20030092090A1 (en) * 2001-11-14 2003-05-15 Kiamars Hajizadeh Rapid prion-detection device, system, and test kit
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
FR2849205B1 (fr) * 2002-12-20 2005-02-11 Afssa Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification
US20040192887A1 (en) * 2003-03-25 2004-09-30 Ralph Zahn PH-dependent polypeptide aggregation and its use
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20050256425A1 (en) 2004-05-11 2005-11-17 Inpro Biotechnology, Inc. Device, system and method for extracting and preparing brain tissue
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
EP2199801B1 (de) * 2004-07-14 2013-05-29 The Regents of The University of California Biomarker zur Früherkennung von Eierstockkrebs
US20080027025A1 (en) * 2004-08-27 2008-01-31 The Regents Of The University Of California Protection From And Treatment Of Prion Protein Infection
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2006102099A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR HUMAN AND BOVINE PrP
JP4724816B2 (ja) * 2005-09-06 2011-07-13 シャープ株式会社 タンパク質の測定方法
US20070196863A1 (en) * 2006-02-17 2007-08-23 Hanson Technologies, Inc. Prion protein detection
JP5097206B2 (ja) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
EP2282753A1 (de) * 2008-04-30 2011-02-16 Novartis AG Assay für pathogene conformer
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
CN104781271B (zh) 2012-08-20 2018-07-06 加利福尼亚大学董事会 具有生物可逆的基团的多核苷酸
JP7178607B2 (ja) * 2018-02-23 2022-11-28 学校法人麻布獣医学園 アミロイドタンパク質を抽出する試薬
US20240199857A1 (en) * 2022-12-16 2024-06-20 The Chinese University Of Hong Kong Chaotropes-assisted deep immunostaining

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
EP0613495B1 (de) * 1991-11-14 2005-02-02 WEISSMANN, Charles Transgene nicht-menschliche tiere ohne prionprotein
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
WO1997043649A1 (en) * 1996-05-14 1997-11-20 Winnacker Ernst Ludwig CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen

Also Published As

Publication number Publication date
WO1998037411A1 (en) 1998-08-27
AU725844B2 (en) 2000-10-19
DE970372T1 (de) 2001-10-25
AU6168898A (en) 1998-09-09
DE69823985D1 (de) 2004-06-24
JP3774236B2 (ja) 2006-05-10
BR9807600A (pt) 2000-02-22
EP0970372B1 (de) 2004-05-19
DE69823985T2 (de) 2005-07-21
JP2001516448A (ja) 2001-09-25
EP1416281A2 (de) 2004-05-06
US5891641A (en) 1999-04-06
EP1416281A3 (de) 2004-05-19
EP0970372A4 (de) 2002-04-10
ES2218807T3 (es) 2004-11-16
CA2278577A1 (en) 1998-08-27
EP0970372A1 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
ATE267394T1 (de) Nachweis der krankheitsbedingten konformation eines proteins
PT807691E (pt) Metodo para a pesquisa quanto a presenca de um defeito genetico associado a trombose e/ou fraca resposta anticoagulante a proteina c activada
ATE509120T1 (de) Fusionsproteine zur detektion von analyten
NZ510703A (en) Assay for disease related conformation of a protein
DK0593618T3 (da) Screeningsassay til påvisning af DNA-bindende molekyler
DE60231651D1 (de) Proteinreinigungsverfahren
ATE439590T1 (de) Verfahren zum selektiven testen von adiponectinmultimeren
BR9804988A (pt) Ensaio para medição de fragmentos de proteìna em meios biológicos.
ATE250143T1 (de) Verfahren und vorrichtung zum nachweis und zur quantifizierung von biomolekülen
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE408422T1 (de) Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
EP0728215A4 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS -g(b)-AMYLOID-PEPTID
DK1887014T3 (da) Humane Toll-homologer
DE69713498D1 (de) Methode zum nachweis übertragbarer spongiformer enzephalopathien
PT641861E (pt) Processo de producao de polipeptidos proteinas ou peptidos hidrofobicos
WO1999030165A3 (en) Processes for identifying a solvent condition suitable for determining a biophysical property of a protein
ATE389881T1 (de) Detektion von kleinen molekülen mit piezo- elektrischem sensor
EP1203775A3 (de) Chemoattraktion-auslösender Faktor aus Lymphozyten und dessen Verwendung
DE59813433D1 (de) Aufreinigung von substanzen aus einer biologischen probe
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
ATE236246T1 (de) Analytisches element, zusammensetzung und verfahren unter verwendung von modifizierter apo- meerrettich-peroxidase
GB9800378D0 (en) Proteome analysis
ES2097158T3 (es) Ensayo funcional para la determinacion de la actividad de proteina s.
ATE312914T1 (de) Rdgb-proteine
Nakamura et al. Fine separation of protein isoforms with alternative development in two-dimensional electrophoresis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties